Reversing multidrug resistance in hepatocellular carcinoma cells by inhibiting extracellular signal‑regulated kinase/mitogen‑activated protein kinase signaling pathway activity

Chen,Siyuan; Wang,Yali; Ruan,Wenwen; Wang,Xiaomin; Pan,Chao

doi:10.3892/ol.2014.2521

Reversing multidrug resistance in hepatocellular carcinoma cells by inhibiting extracellular signal‑regulated kinase/mitogen‑activated protein kinase signaling pathway activity

Authors:
- Siyuan Chen
- Yali Wang
- Wenwen Ruan
- Xiaomin Wang
- Chao Pan
View Affiliations

Affiliations: Department of Pathology, Digestive Diseases Institute, Zhongshan Hospital, Xiamen University, Xiamen, Fujian 361004, P.R. China, Department of Hepatobiliary Surgery, Digestive Diseases Institute, Zhongshan Hospital, Xiamen University, Xiamen, Fujian 361004, P.R. China
Published online on: September 10, 2014 https://doi.org/10.3892/ol.2014.2521
Pages: 2333-2339

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate whether downregulation of extracellular signal‑regulated kinase 1/2 (ERK1/2) is involved in conventional reversal methods and whether the inhibitors of the ERK signaling pathway reverse multidrug resistance (MDR) in hepatocellular carcinoma (HCC) cells. The sensitivities of SMMC7721 and BEL7402, and the MDR SMMC7721/Adriamycin (ADM) and BEL7402/ADM HCC cell lines to ADM were evaluated by CellTiter‑Glo® luminescent cell viability assay through calculating the half maximal inhibitory concentration (IC50) of ADM. In addition, the expression levels of ERK1/2 and phosphorylated (p)ERK1/2 were determined by western blot analysis subsequent to treatment of the cells with PD98059, an MEK inhibitor, or sorafenib, a multikinase inhibitor. The results revealed that the ADM IC50 for the SMMC7721/ADM cells was 16.44 times higher than that of the SMMC7721 cells (P<0.05), and the ADM IC50 for the BEL7402/ADM cells was 20.34 times higher than that of the BEL7402 cells (P<0.05). Following treatment with PD98059 or sorafenib, the expression levels of pERK1/2 in the MDR cells decreased in a dose‑dependent manner. Subsequent to treatment with 5 µM PD98059, the ADM IC50 values for the SMMC7721/ADM and BEL7402/ADM cells were reduced to 0.8±0.056 and 1.583±0.284 µg/ml, respectively. Following treatment with 2.5 µM sorafenib, the ADM IC50 values for the SMMC7721/ADM and BEL7402/ADM cells were reduced to 0.264±0.049 and 1.099±0.135 µg/ml, respectively. Subsequent to incubation with 4 µg/ml cyclosporine A (CsA), a classic MDR reversal agent, the ADM IC50 values in the SMMC7721/ADM and BEL7402/ADM cells were reduced to 0.349±0.023 and 0.427±0.039 µg/ml, respectively. CsA treatment also increased the expression levels of pERK1/2 without affecting the total ERK1/2 levels. Therefore, the inhibition of ERK signaling pathway activity may be an important method to reverse the MDR of HCC cells, but is not unique.

View Figures

View References

1	Tang S, Bao H, Zhang Y, et al: 14-3-3epsilon mediates the cell fate decision-making pathways in response of hepatocellular carcinoma to Bleomycin-induced DNA damage. PLoS One. 8:e552682013.
2	Zhong X, Xiong M, Meng X and Gong R: Comparison of the multi-drug resistant human hepatocellular carcinoma cell line Bel-7402/ADM model established by three methods. J Exp Clin Cancer Res. 29:1152010.
3	Zhang Z, Zhou X, Shen H, Wang D and Wang Y: Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med. 7:412009.
4	Zhu AX: Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist. 11:790–800. 2006.
5	Wakamatsu T, Nakahashi Y, Hachimine D, Seki T and Okazaki K: The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol. 31:1465–1472. 2007.
6	Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002.
7	List AF, Kopecky KJ, Willman CL, et al: Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 98:3212–3220. 2001.
8	Yamamoto K, Kikuchi Y, Kudoh K and Nagata I: Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. J Cancer Res Clin Oncol. 126:168–172. 2000.
9	Holmström TH, Tran SE, Johnson VL, et al: Inhibition of mitogen-activated kinase signaling sensitizes HeLa cells to Fas receptor-mediated apoptosis. Mol Cell Biol. 19:5991–6002. 1999.
10	Cowley GP and Smith ME: Modulation of E-cadherin expression and morphological phenotype in the intravascular component of adenocarcinomas. Int J Cancer. 60:325–329. 1995.
11	Huang C, Jacobson K and Schaller MD: MAP kinases and cell migration. J Cell Sci. 117:4619–4628. 2004.
12	Mansour SJ, Matten WT, Hermann AS, et al: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science. 265:966–970. 1994.
13	Mansour SJ, Resing KA, Candi JM, et al: Mitogen-activated protein (MAP) kinase phosphorylation of MAP kinase kinase: determination of phosphorylation sites by mass spectrometry and site-directed mutagenesis. J Biochem. 116:304–314. 1994.
14	Sturgill TW, Ray LB, Erikson E and Maller JL: Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II. Nature. 334:715–718. 1988.
15	Boulton TG, Nye SH, Robbins DJ, et al: ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell. 65:663–675. 1991.
16	Seger R and Krebs EG: The MAPK signaling cascade. FASEB J. 9:726–735. 1995.
17	Hibi M, Lin A, Smeal T, Minden A and Karin M: Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 7:2135–2148. 1993.
18	Kyriakis JM, Banerjee P, Nikolakaki E, et al: The stress-activated protein kinase subfamily of c-Jun kinases. Nature. 369:156–160. 1994.
19	Han J, Lee JD, Bibbs L and Ulevitch RJ: A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science. 265:808–811. 1994.
20	Freshney NW, Rawlinson L, Guesdon F, et al: Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell. 78:1039–1049. 1994.
21	Rouse J, Cohen P, Trigon S, et al: A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell. 78:1027–1037. 1994.
22	Lee JC, Laydon JT, McDonnell PC, et al: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 372:739–746. 1994.
23	Zhou G, Bao ZQ and Dixon JE: Components of a new human protein kinase signal transduction pathway. J Biol Chem. 270:12665–12669. 1995.
24	Lee JD, Ulevitch RJ and Han J: Primary structure of BMK1: a new mammalian map kinase. Biochem Biophys Res Commun. 213:715–724. 1995.
25	Kohno M, Tanimura S and Ozaki K: Targeting the extracellular signal-regulated kinase pathway in cancer therapy. Biol Pharm Bull. 34:1781–1784. 2011.
26	Yan X, Ruan W, Wang X, et al: The effects of multidrug resistance on cell proliferation, apoptosis and invasion activity and the expression of mitogen-activated protein kinase in human hepatocellular cancer cells. Zhong Liu. 32:507–515. 2012.(In Chinese).
27	Philip PA, Mahoney MR, Allmer C, et al: Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 23:6657–6663. 2005.
28	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007.
29	Geng W, Ng KT, Sun CK, et al: The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma. PLoS One. 6:e273622011.
30	Long Sheng and Maoming Xiong: Progress in primary liver cancer resistant MDR reversal of Hepatobiliary Surgery. 20:236–238. 2012.
31	Dai CL and Fu LW: The development of the reversal of the tumor multidrug resistance. Chin Pharm Bulletin. 21:513–8. 2005.
32	Pétriz J, Sánchez J, Bertrán J and García-López J: Comparative effect of verapamil, cyclosporin A and SDZ PSC 833 on rhodamine 123 transport and cycle in vinblastine-resistant Chinese hamster ovary cells overexpressing P-glycoprotion. Anticancer Drugs. 8:869–875. 1997.
33	Dreuw A, Hermanns HM, Heise R, et al: Interleukin-6-type cytokines upregulate expression of multidrug resistance-associated proteins in NHEK and dermal fibroblasts. J Invest Dermatol. 124:28–37. 2005.
34	Imai Y, Ohmori K, Yasuda S, et al: Breast cancer resistance protein/ABCG2 is differentially regulated downstream of extracellular signal-regulated kinase. Cancer Sci. 100:1118–1127. 2009.
35	Gómez-Martínez A, García-Morales P, Carrato A, et al: Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines. Mol Cancer Res. 5:641–653. 2007.
36	Guan J, Chen XP, Zhu H, et al: Involvement of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line. World J Gastroenterol. 10:3522–3527. 2004.
37	Zhu H, Chen XP, Luo SF, et al: The role of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance of hepatocellular carcinoma. Zhonghua Wai Ke Za Zhi. 45:917–920. 2007.(In Chinese).
38	Kisucká J, Barancík M, Bohácová V and Breier A: Reversal effect of specific inhibitors of extracellular-signal regulated protein kinase pathway on P-glycoprotein mediated vincristine resistance of L1210 cells. Gen Physiol Biophys. 20:439–444. 2001.
39	Chen B, Jin F, Lu P, et al: Effect of mitogen-activated protein kinase signal transduction pathway on multidrug resistance induced by vincristine in gastric cancer cell line MGC803. World J Gastroenterol. 10:795–799. 2004.
40	Li Y, Li S, Han Y, et al: Calebin-A induces apoptosis and modulates MAPK family activity in drug resistant human gastric cancer cells. Eur J Pharmacol. 591:252–258. 2008.
41	Hu Y, Bally M, Dragowska WH and Mayer L: Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis. Mol Cancer Ther. 2:641–649. 2003.
42	Anglicheau D, Pallet N, Rabant M, et al: Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int. 70:1019–1025. 2006.
43	Tanaka S, Hirano T, Saito T, Wakata N and Oka K: P-glycoprotein function in peripheral blood mononuclear cells of myasthenia gravis patients treated with tacrolimus. Biol Pharm Bull. 30:291–296. 2007.
44	Alvarez-Arroyo MV, Yagüe S, Wenger RM, et al: Cyclophilin-mediated pathways in the effect of cyclosporin A on endothelial cells: role of vascular endothelial growth factor. Circ Res. 91:202–209. 2002.
45	Robida AM, Xu K, Ellington ML and Murphy TJ: Cyclosporin A selectively inhibits mitogen-induced cyclooxygenase-2 gene transcription in vascular smooth muscle cells. Mol Pharmacol. 58:701–708. 2000.
46	Chen HW, Chien CT, Yu SL, Lee YT and Chen WJ: Cyclosporine A regulate oxidative stress-induced apoptosis in cardiomyocytes: mechanisms via ROS generation, iNOS and Hsp70. Br J Pharmacol. 137:771–781. 2002.
47	Kiely B, Feldman G and Ryan MP: Modulation of renal epithelial barrier function by mitogen-activated protein kinases (MAPKs): mechanism of cyclosporine A-induced increase in transepithelial resistance. Kidney Int. 63:908–916. 2003.
48	Hojo M, Morimoto T, Maluccio M, et al: Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 397:530–534. 1999.
49	Paslaru L, Trigon S, Kuhlmann M and Morange M: MAP kinase activation by cyclosporine A. Biochem Biophys Res Commun. 236:599–603. 1997.
50	Du MR, Zhou WH, Yan FT, et al: Cyclosporine A induces titin expression via MAPK/ERK signalling and improves proliferative and invasive potential of human trophoblast cells. Hum Reprod. 22:2528–2537. 2007.
51	Zhou WH, Du MR, Dong L, et al: Cyclosporin A increases expression of matrix metalloproteinase 9 and 2 and invasiveness in vitro of the first-trimester human trophoblast cells via the mitogen-activated protein kinase pathway. Hum Reprod. 22:2743–2750. 2007.
52	Cen J and Li YM: Combination therapy on multidrug-resistance tumor. World Notes Antibiotics. 5:224–228. 2009.